Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY™ ...

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced ...

As of Wednesday, December 03, ADC Therapeutics SA’s ADCT share price has dipped by 8.63%, which has investors questioning if ...

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

Diffuse large B-cell lymphoma (DLBCL) is an aggressive blood cancer that kills most untreated patients within one year. Standard CHOP chemotherapy improves five-year survival to 70%—still a ...

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY(TM) ...

The FDA has approved pirtobrutinib for certain adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.The new indication applies to adults who previously have ...

The FDA’s docket in December includes decisions for two big biologic franchises: BMS’s Breyanzi and Amgen’s Uplizna.

Ahead of the upcoming American Society of Hematology (ASH) annual meeting, Alex Niu, MD, of Roswell Park Comprehensive Cancer ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

Using CD22/CD19 CAR T-cell therapy followed by autologous stem cell transplant (ASCT) showed promising results in patients ...

The US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for BeOne Medicines’ B-cell lymphoma 2 ...